Registry Collecting Data on a Rare Blood Cancer Called BPDCN

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The registry is looking for people with a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a very rare blood cancer. It collects data on how the disease is treated.

Sex

All sexes can join.

Disease stage

A diagnosis of BPDCN. No stage is named.

The registry criteria, word for word

What the trial wants to find out

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.